Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gideon Bollag

Showing results (31-40 of 84) with videos related to

Pageof 9
Sort By:
Neoplasia (New York, N.Y.)|August 7, 2010
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanomaWilliam D Tap, Ke-Wei Gong, Judy Dering, et al.
JCI Insight|September 8, 2023
Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activationPan-Yu Chen, Benjamin J Huang, Max Harris, et al.
Cancer Research|December 20, 2011
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancerHong Yang, Brian Higgins, Kenneth Kolinsky, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 2, 2011
The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosisBjoern Buchholz, Bernd Klanke, Gunnar Schley, et al.
Biorxiv : the Preprint Server for Biology|November 26, 2025
Acute Myeloid Leukemia Relapse after Bromodomain Inhibitor Treatment or Chemotherapy is Characterized by Myc-Ras Transcriptional RemodelingBenjamin J Huang, Jeevitha D'Souza, Alexa Rane Batingana, et al.
Pigment Cell & Melanoma Research|October 27, 2010
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomasJohn T Lee, Ling Li, Patricia A Brafford, et al.
JCO Precision Oncology|October 5, 2023
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian CancerLinda R Duska, Dmitriy Zamarin, Erica Hamilton, et al.
Cancer Cell|August 16, 2016
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF SignalingZoi Karoulia, Yang Wu, Tamer A Ahmed, et al.
Molecular Cancer Therapeutics|November 15, 2017
Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas <i>In Vivo</i> and <i>Ex Vivo</i>Edward J Hartsough, Curtis H Kugel, Michael J Vido, et al.
Acta Neuropathologica|October 27, 2012
Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibitionCarlos E Prada, Edwin Jousma, Tilat A Rizvi, et al.
Pageof 9

Showing results (31-40 of 84) with videos related to

Sort By:
Pageof 9
Neoplasia (New York, N.Y.)|August 7, 2010
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanomaWilliam D Tap, Ke-Wei Gong, Judy Dering, et al.
JCI Insight|September 8, 2023
Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activationPan-Yu Chen, Benjamin J Huang, Max Harris, et al.
Cancer Research|December 20, 2011
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancerHong Yang, Brian Higgins, Kenneth Kolinsky, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 2, 2011
The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosisBjoern Buchholz, Bernd Klanke, Gunnar Schley, et al.
Biorxiv : the Preprint Server for Biology|November 26, 2025
Acute Myeloid Leukemia Relapse after Bromodomain Inhibitor Treatment or Chemotherapy is Characterized by Myc-Ras Transcriptional RemodelingBenjamin J Huang, Jeevitha D'Souza, Alexa Rane Batingana, et al.
Pigment Cell & Melanoma Research|October 27, 2010
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomasJohn T Lee, Ling Li, Patricia A Brafford, et al.
JCO Precision Oncology|October 5, 2023
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian CancerLinda R Duska, Dmitriy Zamarin, Erica Hamilton, et al.
Cancer Cell|August 16, 2016
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF SignalingZoi Karoulia, Yang Wu, Tamer A Ahmed, et al.
Molecular Cancer Therapeutics|November 15, 2017
Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas <i>In Vivo</i> and <i>Ex Vivo</i>Edward J Hartsough, Curtis H Kugel, Michael J Vido, et al.
Acta Neuropathologica|October 27, 2012
Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibitionCarlos E Prada, Edwin Jousma, Tilat A Rizvi, et al.
Pageof 9